Trial Profile
S-1/trastuzumab for elderly HER2 positive advanced gastric cancer-Pilot study-
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- 23 Nov 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 23 Nov 2011 New trial record